Skye Bioscience, Inc.

NasdaqGM:SKYE Stock Report

Market Cap: US$77.4m

Skye Bioscience Management

Management criteria checks 1/4

Skye Bioscience's CEO is Punit Dhillon, appointed in Aug 2020, has a tenure of 4.33 years. total yearly compensation is $1.81M, comprised of 24.9% salary and 75.1% bonuses, including company stock and options. directly owns 1.12% of the company’s shares, worth $864.88K. The average tenure of the management team and the board of directors is 2.6 years and 0.8 years respectively.

Key information

Punit Dhillon

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage24.9%
CEO tenure4.3yrs
CEO ownership1.1%
Management average tenure2.6yrs
Board average tenureless than a year

Recent management updates

Recent updates

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Dec 10

Skye: Moving Weight Loss Drugs To The Next Level

Sep 04

Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

Aug 11
Is Skye Bioscience (NASDAQ:SKYE) Using Debt In A Risky Way?

CEO Compensation Analysis

How has Punit Dhillon's remuneration changed compared to Skye Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$21m

Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$2mUS$450k

-US$38m

Sep 30 2023n/an/a

-US$43m

Jun 30 2023n/an/a

-US$21m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$668kUS$433k

-US$19m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$9m

Dec 31 2021US$900kUS$400k

-US$9m

Sep 30 2021n/an/a

-US$8m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$615kUS$160k

-US$7m

Sep 30 2020n/an/a

-US$207k

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

US$13m

Dec 31 2019US$65kn/a

US$1m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$26m

Dec 31 2018US$82kn/a

-US$19m

Compensation vs Market: Punit's total compensation ($USD1.81M) is above average for companies of similar size in the US market ($USD650.00K).

Compensation vs Earnings: Punit's compensation has increased whilst the company is unprofitable.

CEO

Punit Dhillon (44 yo)

4.3yrs

Tenure

US$1,807,338

Compensation

Mr. Punit S. Dhillon, BA, has been Chief Executive Officer of Skye Bioscience, Inc. since August 10, 2020. Mr. Dhillon serves as Chair of Skye Bioscience, Inc. until October 25, 2024. He served as Principa...

Leadership Team

NamePositionTenureCompensationOwnership
Punit Dhillon
President4.3yrsUS$1.81m1.12%
$ 864.9k
Kaitlyn Arsenault
Chief Financial Officer3.2yrsUS$1.27m0.55%
$ 424.2k
Christopher Twitty
Chief Scientific Officer2yrsno datano data
Tu Diep
Chief Development Officerno datano data0.27%
$ 209.8k
Puneet Arora
Chief Medical Officerless than a yearno datano data

2.6yrs

Average Tenure

43.5yo

Average Age

Experienced Management: SKYE's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Punit Dhillon
President6.9yrsUS$1.81m1.12%
$ 864.9k
Paul Grayson
Independent Chairman of the Board1.3yrsUS$1.25m0.86%
$ 662.2k
Andrew Schwab
Director1.3yrsUS$74.08k0.26%
$ 199.8k
Louis Aronne
Member of Clinical & Scientific Advisory Boardless than a yearno datano data
Annalisa Lisa Jenkins
Independent Directorless than a yearno data0%
$ 0
Karen Smith
Directorless than a yearno data0%
$ 0
Deborah Charych
Independent Director1.8yrsUS$102.28k0%
$ 0
Rekha Kumar
Member of Clinical & Scientific Advisory Boardless than a yearno datano data
Lee Kaplan
Member of Clinical & Scientific Advisory Boardless than a yearno datano data
Beverly Tchang
Member of Clinical & Scientific Advisory Boardless than a yearno datano data
Marcus Goncalves
Member of Clinical & Scientific Advisory Boardless than a yearno datano data

0.8yrs

Average Tenure

59yo

Average Age

Experienced Board: SKYE's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 03:52
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Skye Bioscience, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Gum-Ming LoweCraig-Hallum Capital Group LLC
Jonathan WollebenJMP Securities